PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
Abstract BACKGROUND Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization....
Gespeichert in:
Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | viii180 |
---|---|
container_issue | Supplement_8 |
container_start_page | viii180 |
container_title | Neuro-oncology (Charlottesville, Va.) |
container_volume | 26 |
creator | Lazow, Margot Baxter, Patricia Kumar, Shiva Senthil Mohamad, Maya Mackay, Alan Stanek, Joseph Rodriguez, Diana Palmer, Joshua Leach, James Mikael, Leonie Thomas, Diana Fuller, Christine Boué, Daniel Pierson, Christopher Breneman, John Li, Xiao-Nan Salloum, Ralph Ashley, David de Blank, Peter Hwang, Eugene Leary, Sarah Plant, Ashley Fisher, Michael Chi, Susan Murala, Mythili Weetall, Marla Rance, Mark Baird, John D’Silva, Dhiren O’Keefe, Kylie Leonard, Jeffrey Stewart, Clinton Jones, Chris Mardis, Elaine Fouladi, Maryam Drissi, Rachid |
description | Abstract
BACKGROUND
Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization.
METHODS
Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs).
RESULTS
Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (>23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling.
CONCLUSIONS
Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG. |
doi_str_mv | 10.1093/neuonc/noae165.0712 |
format | Article |
fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_0712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.0712</oup_id><sourcerecordid>10.1093/neuonc/noae165.0712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c832-dee8daf0eb6024e6b3f26e45980a42c2f3571660d6d2dd371e2222e91c5b8db23</originalsourceid><addsrcrecordid>eNqNkUGPmzAQhWnVSt1u-wt6mWNyIItNcEhvjjFg1bGRMY1yQiQYqVWbrIL2sP--Toi01_rikWa-p_f0guAbihYoWsdPJ_dyPh2fTufOIZIsohXC74MHlOA4TFJCPtxmHKYJWn0KPo_j7yjCKCHo4V1YUVuGKF7AVkvOGkkNUJXBRmipiz0wbQyX1IqfHAyvG2lryI3egi05VCWtOaANWCOoBJ1Do3i9aaRQMKssS9ZkDjthSzA0E9ojhlZ78FtWCpkZrkDxndyHmaCF0jXPputM5HnjlYXywqoWDCqtrFAcCin0lsIsE1UxvxktRVGGhdd_W5ZFMf8O1PuttLFvdpmWkm60mdIobnfa_IBcGz83RodasXtoH0Awn-iWq4YZ00pxZudfgo9D92d0X-__Y2BzblkZeuwKhMc0xmHvXNp3Q-QOJMJLRw7xgIlbJus06pb4iIc4WSFCop70uO_jFXLYP7dGx-SQ9gccPwbxJHu8nMfx4ob2-fLrb3d5bVHUXgtvp8Lbe-HttXBPLSbq_PL8X8A_urGaKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</creator><creatorcontrib>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</creatorcontrib><description>Abstract
BACKGROUND
Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization.
METHODS
Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs).
RESULTS
Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (>23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling.
CONCLUSIONS
Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.0712</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Lazow, Margot</creatorcontrib><creatorcontrib>Baxter, Patricia</creatorcontrib><creatorcontrib>Kumar, Shiva Senthil</creatorcontrib><creatorcontrib>Mohamad, Maya</creatorcontrib><creatorcontrib>Mackay, Alan</creatorcontrib><creatorcontrib>Stanek, Joseph</creatorcontrib><creatorcontrib>Rodriguez, Diana</creatorcontrib><creatorcontrib>Palmer, Joshua</creatorcontrib><creatorcontrib>Leach, James</creatorcontrib><creatorcontrib>Mikael, Leonie</creatorcontrib><creatorcontrib>Thomas, Diana</creatorcontrib><creatorcontrib>Fuller, Christine</creatorcontrib><creatorcontrib>Boué, Daniel</creatorcontrib><creatorcontrib>Pierson, Christopher</creatorcontrib><creatorcontrib>Breneman, John</creatorcontrib><creatorcontrib>Li, Xiao-Nan</creatorcontrib><creatorcontrib>Salloum, Ralph</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>de Blank, Peter</creatorcontrib><creatorcontrib>Hwang, Eugene</creatorcontrib><creatorcontrib>Leary, Sarah</creatorcontrib><creatorcontrib>Plant, Ashley</creatorcontrib><creatorcontrib>Fisher, Michael</creatorcontrib><creatorcontrib>Chi, Susan</creatorcontrib><creatorcontrib>Murala, Mythili</creatorcontrib><creatorcontrib>Weetall, Marla</creatorcontrib><creatorcontrib>Rance, Mark</creatorcontrib><creatorcontrib>Baird, John</creatorcontrib><creatorcontrib>D’Silva, Dhiren</creatorcontrib><creatorcontrib>O’Keefe, Kylie</creatorcontrib><creatorcontrib>Leonard, Jeffrey</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Jones, Chris</creatorcontrib><creatorcontrib>Mardis, Elaine</creatorcontrib><creatorcontrib>Fouladi, Maryam</creatorcontrib><creatorcontrib>Drissi, Rachid</creatorcontrib><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract
BACKGROUND
Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization.
METHODS
Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs).
RESULTS
Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (>23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling.
CONCLUSIONS
Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkUGPmzAQhWnVSt1u-wt6mWNyIItNcEhvjjFg1bGRMY1yQiQYqVWbrIL2sP--Toi01_rikWa-p_f0guAbihYoWsdPJ_dyPh2fTufOIZIsohXC74MHlOA4TFJCPtxmHKYJWn0KPo_j7yjCKCHo4V1YUVuGKF7AVkvOGkkNUJXBRmipiz0wbQyX1IqfHAyvG2lryI3egi05VCWtOaANWCOoBJ1Do3i9aaRQMKssS9ZkDjthSzA0E9ojhlZ78FtWCpkZrkDxndyHmaCF0jXPputM5HnjlYXywqoWDCqtrFAcCin0lsIsE1UxvxktRVGGhdd_W5ZFMf8O1PuttLFvdpmWkm60mdIobnfa_IBcGz83RodasXtoH0Awn-iWq4YZ00pxZudfgo9D92d0X-__Y2BzblkZeuwKhMc0xmHvXNp3Q-QOJMJLRw7xgIlbJus06pb4iIc4WSFCop70uO_jFXLYP7dGx-SQ9gccPwbxJHu8nMfx4ob2-fLrb3d5bVHUXgtvp8Lbe-HttXBPLSbq_PL8X8A_urGaKA</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Lazow, Margot</creator><creator>Baxter, Patricia</creator><creator>Kumar, Shiva Senthil</creator><creator>Mohamad, Maya</creator><creator>Mackay, Alan</creator><creator>Stanek, Joseph</creator><creator>Rodriguez, Diana</creator><creator>Palmer, Joshua</creator><creator>Leach, James</creator><creator>Mikael, Leonie</creator><creator>Thomas, Diana</creator><creator>Fuller, Christine</creator><creator>Boué, Daniel</creator><creator>Pierson, Christopher</creator><creator>Breneman, John</creator><creator>Li, Xiao-Nan</creator><creator>Salloum, Ralph</creator><creator>Ashley, David</creator><creator>de Blank, Peter</creator><creator>Hwang, Eugene</creator><creator>Leary, Sarah</creator><creator>Plant, Ashley</creator><creator>Fisher, Michael</creator><creator>Chi, Susan</creator><creator>Murala, Mythili</creator><creator>Weetall, Marla</creator><creator>Rance, Mark</creator><creator>Baird, John</creator><creator>D’Silva, Dhiren</creator><creator>O’Keefe, Kylie</creator><creator>Leonard, Jeffrey</creator><creator>Stewart, Clinton</creator><creator>Jones, Chris</creator><creator>Mardis, Elaine</creator><creator>Fouladi, Maryam</creator><creator>Drissi, Rachid</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</title><author>Lazow, Margot ; Baxter, Patricia ; Kumar, Shiva Senthil ; Mohamad, Maya ; Mackay, Alan ; Stanek, Joseph ; Rodriguez, Diana ; Palmer, Joshua ; Leach, James ; Mikael, Leonie ; Thomas, Diana ; Fuller, Christine ; Boué, Daniel ; Pierson, Christopher ; Breneman, John ; Li, Xiao-Nan ; Salloum, Ralph ; Ashley, David ; de Blank, Peter ; Hwang, Eugene ; Leary, Sarah ; Plant, Ashley ; Fisher, Michael ; Chi, Susan ; Murala, Mythili ; Weetall, Marla ; Rance, Mark ; Baird, John ; D’Silva, Dhiren ; O’Keefe, Kylie ; Leonard, Jeffrey ; Stewart, Clinton ; Jones, Chris ; Mardis, Elaine ; Fouladi, Maryam ; Drissi, Rachid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c832-dee8daf0eb6024e6b3f26e45980a42c2f3571660d6d2dd371e2222e91c5b8db23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lazow, Margot</creatorcontrib><creatorcontrib>Baxter, Patricia</creatorcontrib><creatorcontrib>Kumar, Shiva Senthil</creatorcontrib><creatorcontrib>Mohamad, Maya</creatorcontrib><creatorcontrib>Mackay, Alan</creatorcontrib><creatorcontrib>Stanek, Joseph</creatorcontrib><creatorcontrib>Rodriguez, Diana</creatorcontrib><creatorcontrib>Palmer, Joshua</creatorcontrib><creatorcontrib>Leach, James</creatorcontrib><creatorcontrib>Mikael, Leonie</creatorcontrib><creatorcontrib>Thomas, Diana</creatorcontrib><creatorcontrib>Fuller, Christine</creatorcontrib><creatorcontrib>Boué, Daniel</creatorcontrib><creatorcontrib>Pierson, Christopher</creatorcontrib><creatorcontrib>Breneman, John</creatorcontrib><creatorcontrib>Li, Xiao-Nan</creatorcontrib><creatorcontrib>Salloum, Ralph</creatorcontrib><creatorcontrib>Ashley, David</creatorcontrib><creatorcontrib>de Blank, Peter</creatorcontrib><creatorcontrib>Hwang, Eugene</creatorcontrib><creatorcontrib>Leary, Sarah</creatorcontrib><creatorcontrib>Plant, Ashley</creatorcontrib><creatorcontrib>Fisher, Michael</creatorcontrib><creatorcontrib>Chi, Susan</creatorcontrib><creatorcontrib>Murala, Mythili</creatorcontrib><creatorcontrib>Weetall, Marla</creatorcontrib><creatorcontrib>Rance, Mark</creatorcontrib><creatorcontrib>Baird, John</creatorcontrib><creatorcontrib>D’Silva, Dhiren</creatorcontrib><creatorcontrib>O’Keefe, Kylie</creatorcontrib><creatorcontrib>Leonard, Jeffrey</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Jones, Chris</creatorcontrib><creatorcontrib>Mardis, Elaine</creatorcontrib><creatorcontrib>Fouladi, Maryam</creatorcontrib><creatorcontrib>Drissi, Rachid</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lazow, Margot</au><au>Baxter, Patricia</au><au>Kumar, Shiva Senthil</au><au>Mohamad, Maya</au><au>Mackay, Alan</au><au>Stanek, Joseph</au><au>Rodriguez, Diana</au><au>Palmer, Joshua</au><au>Leach, James</au><au>Mikael, Leonie</au><au>Thomas, Diana</au><au>Fuller, Christine</au><au>Boué, Daniel</au><au>Pierson, Christopher</au><au>Breneman, John</au><au>Li, Xiao-Nan</au><au>Salloum, Ralph</au><au>Ashley, David</au><au>de Blank, Peter</au><au>Hwang, Eugene</au><au>Leary, Sarah</au><au>Plant, Ashley</au><au>Fisher, Michael</au><au>Chi, Susan</au><au>Murala, Mythili</au><au>Weetall, Marla</au><au>Rance, Mark</au><au>Baird, John</au><au>D’Silva, Dhiren</au><au>O’Keefe, Kylie</au><au>Leonard, Jeffrey</au><au>Stewart, Clinton</au><au>Jones, Chris</au><au>Mardis, Elaine</au><au>Fouladi, Maryam</au><au>Drissi, Rachid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii180</spage><epage>viii180</epage><pages>viii180-viii180</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract
BACKGROUND
Within the CONNECT1702 trial of unesbulin (tubulin-binding agent causing BMI-1 modulation) with radiotherapy in patients with DIPG/HGG, tumor tissue was analyzed at diagnosis and/or autopsy for biology correlatives, enabling comprehensive, longitudinal molecular characterization.
METHODS
Whole genome sequencing, RNA-sequencing, and Western blot analyses were performed on tumor, normal brain, and peripheral blood mononuclear cells (PBMCs).
RESULTS
Tumor tissue from diagnosis (n=11) and/or autopsy (n=7) was analyzed for 16 patients (DIPG=9; HGG=7). Western blot analyses demonstrated 1) BMI-1 overexpression in baseline tumor compared to normal brain and 2) primary on-target effect of BMI1-modulation causing M-phase mitotic arrest when comparing pre- and post-treated PBMCs (increased H3S10-phosphorylation). Among 9 DIPG patients, alterations in the following genes were identified: H3-3A (H3.3) (n=5), H3C2 (H3.1) (n=2, both with co-occurring ACVR1 and PIK3CA mutations), TP53 (n=5), ATRX (n=2), and PPM1D (n=2). Tumors from two longer DIPG survivors were H3.1-, ACVR1-mutant (overall survival [OS]=26 months) and MET-amplified (OS=18 months); one patient with H3.3K27M-DIPG had germline MSH6 mutation (Lynch syndrome) (OS=12.6 months). Among 7 HGG patients, alterations in the following genes were identified: H3-3A (n=5), TP53 (n=3), NF1 (n=3), PDGFRA (n=1), EGFR (n=1), and PIK3CA (n=1). A BRAFV600E mutation was observed in the thalamic HGG patient (H3.3K27M) with greatest progression-free survival (>23 months). Early leptomeningeal metastases occurred in one DIPG patient with BCOR alteration and one HGG patient, with MYCN amplification identified in the spinal metastasis, but not intracranial disease. From gene set enrichment analyses, pathways enriched in patients with longer survival included telomerase regulation and ATP synthesis, whereas pathways enriched in patients with shorter survival included interneuron development, neuron semaphorin signaling, and gamma aminobutyric signaling.
CONCLUSIONS
Comprehensive molecular profiling of diagnostic and post-mortem tumor tissue provides valuable early biological insight, elucidating potential genomic biomarkers predictive of outcome and response to M-phase alteration and BMI-1 modulation in DIPG/HGG.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.0712</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-8517 |
ispartof | Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii180-viii180 |
issn | 1522-8517 1523-5866 |
language | eng |
recordid | cdi_crossref_primary_10_1093_neuonc_noae165_0712 |
source | Oxford University Press Journals All Titles (1996-Current) |
title | PATH-13. MOLECULAR AND BIOLOGY CORRELATIVE RESULTS FROM THE PHASE 1B TRIAL OF UNESBULIN (PTC596) WITH RADIOTHERAPY IN CHILDREN NEWLY-DIAGNOSED WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T06%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PATH-13.%20MOLECULAR%20AND%20BIOLOGY%20CORRELATIVE%20RESULTS%20FROM%20THE%20PHASE%201B%20TRIAL%20OF%20UNESBULIN%20(PTC596)%20WITH%20RADIOTHERAPY%20IN%20CHILDREN%20NEWLY-DIAGNOSED%20WITH%20DIFFUSE%20INTRINSIC%20PONTINE%20GLIOMA%20(DIPG)%20AND%20HIGH-GRADE%20GLIOMA%20(HGG):%20A%20REPORT%20FROM%20THE%20COLLABORATIVE%20NETWORK%20FOR%20NEURO-ONCOLOGY%20CLINICAL%20TRIALS%20(CONNECT)&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Lazow,%20Margot&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii180&rft.epage=viii180&rft.pages=viii180-viii180&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.0712&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.0712%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.0712&rfr_iscdi=true |